TNSN03123A1 - Inhibiteur de pde 4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes - Google Patents

Inhibiteur de pde 4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Info

Publication number
TNSN03123A1
TNSN03123A1 TNPCT/EP2002/005726A TNSN03123A TNSN03123A1 TN SN03123 A1 TNSN03123 A1 TN SN03123A1 TN SN03123 A TNSN03123 A TN SN03123A TN SN03123 A1 TNSN03123 A1 TN SN03123A1
Authority
TN
Tunisia
Prior art keywords
treatment
inhibitor
pde
anticholinergic agent
obstructive airway
Prior art date
Application number
TNPCT/EP2002/005726A
Other languages
English (en)
Inventor
Michael Yeadon
Roisin A Armstrong
John W Watson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129396A external-priority patent/GB0129396D0/en
Priority claimed from GB0210240A external-priority patent/GB0210240D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN03123A1 publication Critical patent/TNSN03123A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE UNE ASSOCITION D'UN INHIBITEUR DE PDE4 SELECTIF ET D'UN AGENT ANTICHOLINERGIQUE POUR UNE ADMINISTRATION, SIMULTANEE, SEQUENTIELLE OU DISTNCTE, PAR INHALATION, DANS LE TRAITEMENT D'UNE MALADIE OBSTRUCTIVE DES VOIES AERIENNES OU UNE AUTRE MALADIE INFLAMMATOIRE, SOUS RESERVE QUE L'AGENT ANTI-CHOLINERGIQUE NE SOIT PAS UN SEL DE TIOTROPIUM.
TNPCT/EP2002/005726A 2001-05-25 2003-07-08 Inhibiteur de pde 4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes TNSN03123A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29360601P 2001-05-25 2001-05-25
GB0129396A GB0129396D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
GB0210240A GB0210240D0 (en) 2002-05-03 2002-05-03 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
TNSN03123A1 true TNSN03123A1 (fr) 2005-12-23

Family

ID=27256347

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/EP2002/005726A TNSN03123A1 (fr) 2001-05-25 2003-07-08 Inhibiteur de pde 4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Country Status (25)

Country Link
US (1) US20040147544A1 (fr)
EP (1) EP1395288A1 (fr)
JP (1) JP2005508861A (fr)
KR (1) KR20040007605A (fr)
CN (1) CN1511042A (fr)
AP (1) AP2003002909A0 (fr)
BG (1) BG108382A (fr)
BR (1) BR0209992A (fr)
CA (1) CA2446613A1 (fr)
CO (1) CO5640041A2 (fr)
CR (1) CR7152A (fr)
CZ (1) CZ20033150A3 (fr)
EE (1) EE200300585A (fr)
HU (1) HUP0400037A2 (fr)
IL (1) IL158776A0 (fr)
MA (1) MA27027A1 (fr)
MX (1) MXPA03010162A (fr)
NO (1) NO20035204D0 (fr)
NZ (1) NZ529335A (fr)
OA (1) OA12610A (fr)
PA (1) PA8546001A1 (fr)
PL (1) PL367085A1 (fr)
SK (1) SK14312003A3 (fr)
TN (1) TNSN03123A1 (fr)
WO (1) WO2002096463A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2519682A1 (fr) * 2003-03-28 2004-10-07 Altana Pharma Ag Association synergique contenant du roflumilast et un agent anticholinergique selectionne parmi les sels d'ipratropium, d'oxitropium et de tiotropium et destinee au traitement de maladies respiratoires
PT1610787E (pt) * 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
SI1713471T1 (sl) * 2004-02-06 2012-07-31 Meda Pharma Gmbh & Co Kg Kombinacija antiholinergikov in inhibitorjev fosfodiesteraze tipa za zdravljenje respiratornih bolezni
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
WO2005102344A1 (fr) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. Composition pharmaceutique
PL1634595T3 (pl) * 2004-08-19 2009-01-30 Rottapharm Spa Pochodne N-fenylobenzamidu jako leki do leczenia COPD
MX2007011273A (es) 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
KR100696432B1 (ko) * 2005-08-31 2007-03-19 김용환 건강진단용 팬티
EP1948167A1 (fr) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions d'inhibiteurs de la phosphodiesterase de type iv
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
AU2006329042B2 (en) 2005-12-21 2012-02-02 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
US6004974A (en) * 1995-06-06 1999-12-21 Pfizer Inc Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

Also Published As

Publication number Publication date
US20040147544A1 (en) 2004-07-29
CZ20033150A3 (cs) 2004-06-16
CR7152A (es) 2004-02-23
HUP0400037A2 (hu) 2004-04-28
NO20035204D0 (no) 2003-11-24
CN1511042A (zh) 2004-07-07
MXPA03010162A (es) 2004-03-10
PA8546001A1 (es) 2003-12-30
AP2003002909A0 (en) 2003-12-31
CA2446613A1 (fr) 2002-12-05
SK14312003A3 (sk) 2004-08-03
EE200300585A (et) 2004-04-15
IL158776A0 (en) 2004-05-12
EP1395288A1 (fr) 2004-03-10
KR20040007605A (ko) 2004-01-24
PL367085A1 (en) 2005-02-21
BR0209992A (pt) 2004-04-06
BG108382A (bg) 2004-12-30
JP2005508861A (ja) 2005-04-07
CO5640041A2 (es) 2006-05-31
WO2002096463A1 (fr) 2002-12-05
OA12610A (en) 2006-06-09
MA27027A1 (fr) 2004-12-20
NZ529335A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
TNSN03123A1 (fr) Inhibiteur de pde 4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
JO2503B1 (en) Benzathiazole derivatives
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
HUP0004350A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
HK1079445A1 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
WO2002085248A3 (fr) Prostanoides pouvant augmenter la penetration de medicaments oculaires
WO2006020581A3 (fr) Prevention et traitement de maladies synucleinopathique et amyloidogenique
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
BG105173A (en) Novel salt form of pantoprazole
MY135838A (en) Methods for the treatment of mental disorders
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
HK1090543A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2003053923A3 (fr) Derives de pyrrolidine utilises en tant que modulateurs de la prostaglandine
BR0007613A (pt) Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
SG121745A1 (en) Cabergoline and pramipexole: new uses and combinations
WO2000076500A8 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
HUP0303910A2 (hu) Húgyhólyagbetegségek kezelésére szolgáló kappa-opiát agonisták alkalmazása gyógyszerkészítmények előállítására
TNSN03124A1 (fr) Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
WO2002074288A3 (fr) Composés chimiques
WO2003000269A3 (fr) Nouvelle utilisation d'inhibiteurs de pde 10a